Article
Implementing genotype-guided antithrombotic therapy.
Future cardiology - 1 May 2010
Seip Richard L, Duconge Jorge, Ruaño Gualberto
Abstract excerpt
Genotyping has the potential to improve the efficacy and safety of major antithrombotic drugs. For warfarin, the stable maintenance dose varies from 1-10 mg/day. The VKORC1 -1639G>A allele and the CYP2C9*2 and *3 alleles (cumulative frequency: 90% in Asians, 65% in Europeans and 20% in Africans), explain 45% of response variability in European and 30% in African populations. The large clinical trials COAG and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.